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Abstract
Lung cancer is a major health burden accounting for 1.59 million deaths worldwide. For both sub-types of lung
cancer (NSCLC and SCLC), chemotherapy is an option. However, success is limited and side effects are detrimental
to an individuals’ overall quality of life. To complicate matters further, cancer cells can develop resistance to
chemotherapeutic agents due to the presence of membrane associated proteins such as P-glycoprotein and Multi-
drug resistance-associated protein. Thus it is, imperative that new drug treatments are developed that have neither
the toxicity nor mechanisms of resistance associated with conventional chemotherapy.
In recent years, antimicrobial peptides (AMPs) have attracted attention as potential anti-cancer drugs due to
reports that they can selectively target and kill cancer cells while leaving normal healthy cells unaffected. This review
summaries several studies and discusses whether AMPs could be a viable treatment option in the fight against lung
cancer.
Keywords: Antimicrobial peptides; Cancer; Lung cancer;
Therapeutics; Anti-cancer
Introduction
In 2012 it was reported that there was an estimated 14 million new
cancer cases and 8.2 million cancer related deaths worldwide with lung
cancer being the most common cause of death [1]. In the UK and
USA, lung cancer is the second most common cause of cancer for both
males and females and accounts for around 35,400 and 158,100 deaths
per year respectively [2,3]. The majority of lung cancers arise in
epithelial cells and can broadly be divided into two sub-groups: non-
small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)
which account for 85% and 15% of all lung cancer cases respectively. In
addition there are three main sub-types of NSCLC; squamous cell lung
carcinoma, large cell lung carcinoma and adenocarcinoma [4].
SCLC is treated mostly with chemotherapy whereas NSCLC can be
treated with chemotherapy, surgery, radiotherapy or a combination of
these treatments depending on the stage at which the cancer is
diagnosed [2]. While several treatment options exist, chemotherapy
remains the treatment choice for advanced/metastatic disease. Unlike
other cancers such as breast and prostate, survival rates for lung cancer
have not shown great improvements. Only 5% of people with lung
cancer are alive 10 years after diagnosis as over two thirds are
diagnosed at an advanced stage when curative treatment is not
currently possible [2]. Thus, while chemotherapy is given to people
with late stage lung cancer its success is limited. Furthermore, due to
the fact chemotherapeutic drugs are non-specific in terms of the type
of dividing cells they target they are also toxic to normal dividing cells
causing deleterious side effects such as nausea, diarrhoea, hair loss,
anaemia and infections. Toxic effects on normal cells aside, cancer cells
can develop resistance to chemotherapeutic drugs due to the presence
of membrane associated proteins such as P-glycoprotein and the
multidrug resistance–associated protein (MRP) [5] that act as efflux
pumps. With specific regard to lung cancer it has been reported that
90% of SCLC tumours will initially respond to chemotherapy, but
patients almost always relapse with multidrug-resistant disease while
the NSCLC tumours has a much lower response rate due to inherent
drug resistance [6]. There is only a 10-20%, 5 year survival rate for
NSCLC due to the aggressiveness of the disease and the lack of
effective treatments [7]. It is, therefore, imperative that new drug
treatments are developed that have neither the toxicity nor
mechanisms of resistance associated with conventional chemotherapy.
Antimicrobial Peptides
Antimicrobial peptides (AMPs) are a group of compounds that are a
conserved element of the innate immune response [8]. Found in all
species investigated such as bacteria, fungi, plants, insects, birds, fish,
amphibians and mammals [8,9] these small peptides are between
12-50 amino acids long [10] and have been shown to effectively kill a
wide range of micro-organisms such as viruses, fungi and both gram-
negative and gram-positive bacteria [11]. AMPs in animals are
expressed by a wide variety of cells such as epithelial cells of the
stomach, skin, and respiratory tract, mast cells, monocytes and
neutrophils [12]. To date, over 5000 AMPs have been discovered or
synthesised [13]. AMPs are grouped into two sets; those which are
toxic towards bacteria and cancer cells but not to mammalian cells and
those which are cytotoxic towards bacteria, cancer cells and normal
mammalian cells [14]. AMPs which are nontoxic towards mammalian
cells hold great potential in cancer therapy. Not all AMPs possess
anticancer properties but those that do, Anti-Cancer Peptides (ACPs),
have been recognised to be more specific in their effects producing less
harmful side effects than chemotherapy and traditional therapies [15].
Many different characteristics, properties and delivery combinations
have been pinned as contributing factors for the ACPs to express their
selective nature towards cancer cells.
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Mechanisms Involved in AMP Induced Cell Death
AMPs act by several mechanisms–barrel stave, toroidal, carpet
model, and the aggregate channel model [16,17]. With the exception of
the barrel-stave model, the other models are still open to disagreement
regarding their mode of actions as well as currently lacking any clear
distinction between their characteristics [17]. However it would appear
that the overall mechanism favoured by the AMPs is dependent upon
the amino acid sequence, amphipathicity, cationic charge and size of
the peptide [18].
Barrel stave, the most widely accepted mechanism, is characterised
by its process of membrane disruption, producing a highly organised
cylindrical pore [19]. The AMP is attracted to the cancer cell (via the
properties mentioned below). Once on the cell the AMP can bind to
the cell membrane anchoring it into place [20]. The peptides then
expose their hydrophobic amino acids to the lipid bilayer within the
membrane, connecting the two membranes, forcing a conformational
change in the membrane and forming a transmembrane pore (Figure
1) [21,22]. This pore formation results in the cellular material leaking
out of the cell resulting in the cell death.
Figure 1: AMP induced mechanisms of death. The mechanisms of
action by which AMPs act upon cell membranes resulting in cell
death. (A) Barrel-Stave model. AMP molecules insert themselves
into the membrane perpendicularly, connecting the two layers of
the membrane to form a transmembrane pore. (B) Carpet model.
Small areas of the membrane are coated with AMP molecules with
hydrophobic sides facing inward leaving pores behind in the
membrane. (C) Toroidal pore model. This model resembles
integration between the AMP and the lipid bilayer [22].
The toroidal model is very similar in characteristics to those of the
barrel stave model, in that they both form pores within the membrane
of the target cell. However there are some important differences which
distinguish the two models. In the toroidal model when the peptides
expose the hydrophobic amino acid residues to the lipid core of the
membrane- instead of forcing a conformational change–the peptides
and lipids integrate together forming torus pores spanning the
membrane [20]. The target cell membrane thins whilst the phosphate
head groups of the lipids expand forcing the membrane bilayer to
curve and bend [19]. Toroidal pores characteristically form very short
ARG Cζ P distances within the membrane [21].
Cζ of ARG describes the distance between Arginine-Arginine
residues within the membrane structure; the short distance is due to
strong electrostatic interactions between the residues-typically shown
close to the surface of membranes [23]. Once the channel is formed the
intracellular material leaks out of the target cell leading to cell death. It
has been suggested that the strongest bonding between AMPs and
their target cell membrane is through the use of the toroidal method
[24].
The carpet model (Carpet-like model) acts very differently to both
the barrel stave and toroidal model. A key characteristic of this model
highlighted by Liu et al. is the necessity for the AMP concentration to
reach a threshold limit (AMP and cancer type dependent) in order for
cell death to be instigated. Although a threshold is needed to instigate
the mechanism, a high peptide to lipid ratio is also necessary [25]. The
hydrophilic amino acids within the AMP sequences are attracted to the
phospholipid heads of the membrane bilayer, as seen in Figure 2. The
bound AMPs disrupt the curved anionic membrane, associating with
the inner membrane of the target cell [26]. The peptides reorganise to
surround the cell membrane and acts indirectly to dissolve the cell
membrane, killing the target cell.
Figure 2: AMP structures. The structural diversity of naturally
occurring AMPs. A-D; are α- helices, E-H; show the β- sheet
structure from differing perspectives, I-K; αβ peptides, L; non-αβ.
Properties of AMPs
AMPs are specifically selective for cancer cells over normal
epithelial cells and this is generally attributed to several complimenting
characteristics between the cancer cell membranes and the AMPs.
Such characteristics include their ability to interact electrostatically
with each other, membrane fluidity, and cholesterol content of the cell
membrane and the hydrophobicity of the AMP.
Hydrophobicity and electrostatic interaction
AMPs are generally cationic, that is they have a net positive charge
of +2 to +7 due to an excess of basic amino acid such as arginine, lysine
and histidine while 50% or more of the amino acids are hydrophobic
[27]. In contrast to the positive charge of the AMPs, cancer cells
typically have a net negative charge due to over expression of anionic
molecules and increased o-glycosylated mucins on their surface [28].
The contrasting net charges induce an electrostatic interaction between
the AMPs and the cancer cell membrane. The electrostatic interaction
creates a strong binding of the AMP onto the target cell and provides
specificity for the cancer cells over normal epithelial cells.
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While hydrophobicity has been traditionally associated with the
effectiveness of AMPs to act as anti-cancer agents [20,29] this theory
has now been adapted to recognise that hydrophobicity and
effectiveness (represented as therapeutic index) are not directly
correlated as was once previously thought. Several studies have been
carried out testing the relationship between hydrophobicity and
therapeutic index concluding that the relationship is a bell curve rather
than a linear correlation [25,30,31]. As hydrophobicity of the AMPs
increase the potency and therapeutic index also increases until a
threshold is reached-dependent upon the AMP and the cancer type. As
hydrophobicity increases past this point it has a detrimental impact
upon therapeutic index [25,30]. Huang et al. [25] investigated this
relationship in the lung cancer cell line A549. They showed that a
middle range of hydrophobicity- ~10- 35 μmol/l, therapeutic
index=15.8 to 24.6-resulted in a three/fourfold increase in the
therapeutic index compared to the low or high hydrophobic levels,
therapeutic index=8.8 to 0.5 and 9.1 to 4.0 respectively. The reduction
of therapeutic index results as the increase in hydrophobicity and
potency compromises the selectivity of the AMPs for the target cells
[30]. With reduced selectivity the AMPs are unable to bind to the
cancer cells as specifically reducing the chances of cell death. In
addition to selectivity being compromised, significantly hydrophobic
AMPs (e.g. high content of leucine) have been recognised to self-
associate further reducing their ability to interact with cancer cells
[31].
Membrane fluidity
AMPs can further distinguish between cancer cells and normal
epithelial cells as the membrane fluidity of cancer cells is much greater
[32]. The fluidity of the membrane is a key indicator in cancer
progression. As cancer progresses the cell becomes more open to
conformational change as the fluidity in the membrane increases [33].
AMPs act by creating pores in the membrane to gain intracellular
access. As the membrane fluidity increases the AMPs can penetrate
deeper into the hydrophobic layer of the cancer cells enhancing their
effect [34].
Cholesterol and AMPs
AMPs have a greater impact on cancer cells because cancer cells
have relatively low cholesterol content compared to normal cells
[35,36]. This is due to the cholesterol molecules acting as membrane
protectors through the modulation of membrane fluidity [37]. The
cholesterol hinders the AMPs interaction with the cell membrane,
reducing disruption to the target cell, restricting the chances of cell
death [15].
Structures of AMPs
AMPs can be divided into four categories: (i) unstructured peptides
which upon contact with membranes will fold into amphipathic α-
helical peptides (ii) β-sheet peptides stabilised by disulphide bridges
(iii) αβ peptides, which contain a predominance of one or two amino
acids which contain disulphide bonds and (iv) non- αβ that contain
neither α helices nor β-sheets (Figure 2) [10]. The α-helical structure
plays a key role in determining the hydrophobicity of peptides. This
hydrophobicity is essential for peptide secondary structure and
influences the interaction of the AMP with its target cell membrane.
The peptides are able to associate with each other, and in doing so,
cause transmembrane pores leading to the death of the cell [25]. β-
sheet peptides, which naturally originate from animals, act best as
antibiotics against bacteria [38]. The β-sheet is considered the most
stable of the four categories due to the hydrophobic interactions
between the side chains of the peptides as well as the disulphide
bridges between the chains which increases their stability [39]. β-sheet
peptides are also believed to exert their antimicrobial effects through
membrane disruption [40].
The αβ-structures contain disulphide bonds which are believed to be
responsible for the structure observed in aqueous solution [41].
However, non- αβ AMPs have yet to be investigated thoroughly and
therefore their characteristics are not yet fully understood. So far, α-
helical and β-sheets are the most common configurations of AMPs
with anticancer properties [14,20]. Thus, the structure of the peptide
influences the properties expressed by the AMP and can affect their
potential use in cancer therapy [42].
The specific amino acid sequence of the peptide is also an important
factor contributing to the properties of AMPs and their potential for
anti-cancer effects. The amino acids alanine, leucine isoleucine and
valine are strongly hydrophobic and are found at high levels in AMPs
that exhibit anticancer properties [43]. However, altering the amino
acid sequence via substitution of specific residues affects the
hydrophobicity and secondary structure of the peptides [25]. For
example, leucine is a large hydrophobic residue which helps to stabilise
the α-helical structure. When it is inserted into a peptide sequence the
hydrophobicity of the AMP is increased along with an increase in the
stability of the peptide. Yet, when leucine residues are converted to
alanine residues the overall hydrophobicity of the peptide decreases.
Although alanine is also hydrophobic it is small and so its short side-
chain arms cannot reach the side chains of the neighbouring amino
acids; this reduces the hydrophobicity of the peptide, which in turn
alters its potency and thus, its therapeutic index [25].
AMPs can also be found that are rich in glycine (glycine making up
14-22% of all the amino acid residues). Glycine affects the tertiary
structure formed and thus their mode of action. Glycine is a simple
structural amino acid in that it does not possess a side chain, which
increases the conformational flexibility of the AMP [44]. In an
investigation carried out by Phoenix et al. [44] they found that glycine
rich antimicrobial peptides were twice as likely to be unsuccessful in
displaying anti-cancer properties. They attributed this finding to the
fact that glycine rich AMPs easily undergo conformational change due
to glycine’s lack of a side chain. Glycine rich AMPs therefore have a
reduced natural tendency to form α-helical structures preventing
membrane binding [45]. This would suggest that the amino acid
sequence of the AMP plays a pivotal role in their effectiveness as a
cancer therapy.
AMPs and lung cancer
Mucins are expressed in epithelial cells within the body e.g. lung
and eyes, to protect against infection. It has been recognised that in
lung cancer patients, mucins are over expressed in the lung epithelial
cells-specifically MUC1 and MUC2 [46]. The presence of mucins on
lung cancer cells have been recognised as a negative prognosis
indicator for disease-free survival [47]. However, mucins are also
susceptible to glycosylation. Glycosylation is a common post-
translational modification of proteins which promotes protein folding,
stability, and cell-cell interaction [48]. Mucins are characterised by
repeated stretches called variable number tandem repeats (VNTRs)
that are rich in serine and threonine [49]. A major type of
glycosylation is the O-linked glycosylation [14]. O-glycosylation
occurs when a sugar is attached to the hydroxyl group of a serine or
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threonine. As mucins are rich in these amino acids, O-glycosylation
can be extensive which in turn increases the negative charge of the
cancer cell membrane. In addition, the presence of the glycoprotein
Alpha-1-acid glycoprotein 1, whose overexpression is significantly
associated with NSCLC membranes is also said to aid in the selectivity
of AMPs [50] to cancer cells. Glycosylated mucins could be
advantageous from an AMP treatment perspective, by increasing the
electrostatic attraction between the AMP and the lung cancer cell
membrane. Furthermore, as previously mentioned, the lower
cholesterol content of cancer cell membranes aids the ability of AMPs
to disrupt the lipid bilayer. A study carried out by Kucharska-Newton
et al. [51] showed that high density lipoprotein cholesterol and lung
cancer are inversely associated meaning lung cancer cells have typically
low cholesterol concentrations. Thus, the extensive glycosylation and
low cholesterol content exhibited by lung cancer cell membranes
suggests that AMPs could be successful anti-cancer agents to target
lung cancer.
Several in vitro studies have been carried out investigating the effect
of AMPs on lung cancer cell lines. In a preliminary study performed by
Ohsaki et al. [52] 6 human SCLC cell lines and 4 normal human
fibroblast cell lines were tested for their sensitivity to magainin A and
magainin G–synthetic analogues of the frog antimicrobial peptide
magainin. Results of this investigation showed that magainin A and
magainin G had anti-tumour activity to all 6 lung cancer cell lines but
were not as toxic to the normal human fibroblast cell lines (against the
lung cancer cell lines the average IC50 of magainin A and magainin G
were 8.64 and 8.82 µM respectively, while against normal human
fibroblasts the IC50 of magainin A and magainin G were 21.1 and 29.2
µM respectively). Furthermore, magainin A and magainin G enhanced
the cytotoxicity of the chemotherapeutic agents, cisplatin and
etoposide when used in combination.
Huang et al. [53], carried out investigations on a custom synthesised
peptide, CB1, derived from the natural antimicrobial peptide Cecropin
B. The authors tested CB1a on normal lung epithelial cells (WI-38,
MRC-5, HEL-299 cell lines), NSCLC cells (A549, NCI-H209, NCI-
H460, NCI-H520) SCLC cells (NCI-H146) and an in vivo mouse
model of lung cancer The in vitro testing showed that the CB1a peptide
could selectively kill lung cancer cells without affecting normal lung
cells. The IC50 range for lung cancer cells was 4 to 29 μM whereas for
normal lung cancer cells the IC50 was significantly higher, ranging
from 158 to >300 μM. CB1a also significantly inhibited the growth of
tumours in the in vivo mouse model. Furthermore, the authors also
observed that the CB1a peptide had greater cytotoxicity to lung cancer
cells (in vivo) than the chemotherapeutic agent docetaxel, while still
displaying less toxicity to normal cells.
AMPs in clinical trials
To the best of our knowledge, no AMPs have entered clinical trials
or the drug market to assess their efficacy as a cancer therapeutic.
However peptides, as a whole, are being recognised as selective,
efficacious and well tolerated therapeutic agents. As a result, in 2015
there were approximately 140 peptides drugs in clinical trials and over
500 in preclinical development [54]. Furthermore, of these peptide-
derived therapies several have entered clinical trials aimed at treating
various types of cancers. Once such peptide is asparagine-glycine-
arginine tumor homing peptide (NGR-hTNF). In combination with
Cisplatin, this combination therapy has undergone a phase 1 clinical
trial for use in several refractory solid tumors (such as NSCLC tumors,
colorectal, melanomas, sarcoma, gastric, carcinoid, malignant pleural
mesothelioma (MPM) and solitary fibrous tumor of the pleura (SFTP)
[55]. The patient cohort consisted of 22 patients, age range between 47
and 75, and had previously received systemic therapy before being
recruited to the trial. The solid tumour types used in the trail covered;
the drug combination was delivered once every three weeks for a
minimum of 6 cycles, dependent on disease progression, patient
consent or increased toxicity. Concentrations of the drug combinations
administered varied on an inter-patient basis. The follow up of the trial
showed that seven out of the seventeen patients that completed the
trial showed their disease to stabilise for a median time of 5.9 months
post treatment meaning the tumor did not grow in size or metastasize
during this time. One out of the seventeen patients exhibited a partial
response to the treatment for 6.6 months. The most effective
concentrations which showed to stabilise the disease or initiate a
partial response of halting the tumor growth was found to be 0.8 μg/m2
of NGR-hTNF and 80mg/m2 cisplatin. The outcome of Gregorcs’ et al.
[55] study was for the peptide and cisplatin combination to enter phase
2 clinical trials showing its potential as an anti-tumour agent.
Deplanque et al. [56] reported on a phase 2 clinical trial testing the
peptide IM862, a natural dipeptide (L-glu–L-trp) for treatment in
metastatic renal cell carcinoma (RCC). Twenty five patients were
enrolled on to the trial which had histologically and/or cytologically
proven metastatic RCC [56]. The treatment group was administered 20
mg of IM826 intranasally three times daily for 8 weeks. Eight of the 25
patients’ RCC were reported to have stabilized-for a median of 6
months-meaning the RCC did not grow in size or metastasize to a
condition worse than that prior to the trial. It is important to note the
patients who saw their disease stabilize were of slow progressive RCC.
Even though the drug didn’t prove significant in response towards
RCC, it was observed that IM826 decreased the levels of VEGF in the
patients and therefore has been recommended for further investigation
for its use as an anti-angiogenic agent [56].
In addition to the peptide- derived therapies undergoing clinical
trials, several peptide-derived therapies are currently approved for
delivery by the Food and drug administration (FDA) in the treatment
of specific cancers [54]. For example Lupron TM from Abbott
laboratories is on the market for use in prostate cancer and breast
cancer therapy [57]. In 2011 Lupron TM alone created US $2.3 billion
in global sales- which demonstrates how peptide-derived therapies not
only hold potential for anti-cancer properties, but also how lucrative
the peptide-derived therapies could be to the pharmaceutical industry
[54]. Thus the success of these peptides in the clinic may open the door
for AMPs that have anti-cancer properties to reach the clinical settings.
However, for AMPs to be effective in vivo for lung cancer one
obstacle, in particular, needs to be overcome; this is the salt
concentration in the lung. Salt concentration influences the
effectiveness of AMPs to function on cells. Their efficacy is believed to
be greatly reduced as high salt concentrations inhibit antimicrobial
activities [58]. Encouragingly, recent investigations have been carried
out to improve the resistance of AMPs against increased salt
concentrations. Chu et al. [59] developed a method to enhance the
antimicrobial activity and salt tolerance of short antimicrobial peptides
by modifying their lipophilicity with the addition of the amino acid β-
naphthylanine (Nal) to their N or C terminus, In their paper, Chu et al.
[59] designed a series of Nal-embedded peptides and tested their salt-
tolerance (against antibiotic resistant gram negative and positive
bacteria) and anticancer properties (against lung cancer cell lines PC9
and A549). Their results showed that the addition of Nal, to either the
N-terminus or embedded in the sequence of the peptide, helped the
Citation: Swithenbank L, Morgan C (2017) The Role of Antimicrobial Peptides in Lung Cancer Therapy. J Antimicrob Agents 3: 134. doi:
10.4172/2472-1212.1000134
Page 4 of 6
J Antimicrob Agents, an open access journal
ISSN:2472-1212
Volume 3 • Issue 1 • 1000134
peptide to kill antibiotic resistant bacteria at high salt concentrations.
Furthermore the Nal modified peptide displayed better anti-cancer
activities than their parent peptides with the authors hypothesising
that the Nal residue may help the peptide penetrate further into the
cancer cell membrane, which in turn makes them more efficient at
disrupting the membrane. In addition, some of the Nal modified
peptides were less toxic to human red blood cells and human
fibroblasts and significantly inhibited human lung tumour growth in
nude mice. This study provides evidence that peptides can be designed
to overcome the salt concentration restraints making AMPs a
possibility for lung cancer treatment.
Furthermore the source of the AMP also plays a large role in the
characteristics. For example marine animals have adapted to a very
harsh environment rife with bacteria and therefore marine animals
possess a diverse range of AMPs as a first line of defence [60]. AMPs
from marine animals have evolved to overcome the high salinity of
their natural environment giving them greater resistance to high salt
concentrations than AMPs from other natural environments [60,61].
The marine AMPs resistance to high salt concentrations could be due
to the substitution of lysine amino acids for arginine [60]. These
properties found in marine AMPS could show further potential for
their use in lung cancer therapy.
Conclusion
Survival rates for lung cancer have not shown great improvements.
Many patients present with an advanced form of the disease and at this
stage, the only form of treatment is chemotherapy. Not only does
chemotherapy provide little success the side effects are deleterious due
to the non-specific targeting of the drug. In addition, many cancers,
including lung cancer develop drug resistance over time. Investigation
into AMPs as anti-cancer agents is rapidly increasing. AMPs selectively
target cancer cells and are not affected by the common mechanisms of
chemotherapy resistance that cancer cells display. Several studies have
looked into the anticancer effects of AMPs on lung cancer cell lines
with promising results. Furthermore, research has shown that
extensive glycosylation and low cholesterol levels, characteristic of lung
cancer cell membranes, enhance the affinity of AMPs to bind to cancer
cell membranes. While further investigation into the anti-cancer
potential of AMPs is needed, it is possible that AMPs may offer a
potentially new application in lung cancer therapy.
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